<DOC>
	<DOCNO>NCT01703598</DOCNO>
	<brief_summary>The purpose study determine whether perform deep brain stimulation surgery Parkinson 's disease use intraoperative imaging frameless stereotaxis noninferior use frame-based stereotaxy microelectrode recording .</brief_summary>
	<brief_title>Clinical Outcomes Deep Brain Stimulator ( DBS ) Electrodes Placed Using Intraoperative Computed Tomography ( CT ) Frameless Stereotaxis</brief_title>
	<detailed_description>Background : Frame-based stereotaxis microelectrode recording ( MER ) map target structure gold standard deep brain stimulator ( DBS ) implantation . Though supported historical consideration , Class I II evidence exists MER add significant value DBS implant procedure . With advent advance magnetic resonance imaging ( MRI ) compute tomography ( CT ) imaging , particularly intra-operative imaging , argument continue use MER DBS implantation substantially weaken . One rationale pursue CT-guided intraoperative imaging due presumed increase patient comfort method . DBS implantation MER require patient remain awake entire procedure . , MER frame-based stereotaxis require patient keep head fix position prolong period time time remain awake , cause significant patient discomfort . Furthermore , Parkinson 's disease patient must withhold PD med minimum 12 hour prior procedure add sometimes significant degree discomfort anxiety procedure . Objective : The goal study compare clinical outcome DBS electrode place use intraoperative CT frameless stereotaxis place use MER frame-based stereotaxis . Design : The propose study prospective non-interventional data collection study . Setting Subjects : Subjects study idiopathic Parkinson 's disease patient identify Oregon Health &amp; Science University movement disorder clinic candidate deep brain stimulation therapy . Enrollment continue fifty subject implant electrode use frameless stereotaxis intraoperative CT. Data regarding quality life , motor control , amount time day without levodopa side effect collect pre-operatively post-operatively . This data compare historical control implant DBS electrode use MER frame-based stereotaxis . All surgical procedure involve Federal Drug Administration ( FDA ) approve stereotactic equipment , use manner approve . All clinic procedure standard care movement disorder patient deep brain stimulation program . Intervention : This study non-interventional data collection study . Measurements : Data regard patient age , diagnosis , intracranial target , complication , Unified Parkinson 's Disease Rating Scale UPDRS Parts 3 ( motor examination ) 4 ( drug side effect ) , Parkinson 's Disease Quality life PDQ-39 , 3 day motor diary , 3 month fall diary , neuropsychiatric evaluation day hospital follow surgery collect . Analysis : The patient examine prior DBS placement dopaminergic medication . They examine 3 month 6 month follow DBS placement drug stimulator program parameter optimize . The following measure perform : - Change UPDRS Parts 3 4 - Change PDQ-39 - Change amount time patient experience Parkinson 's disease symptom and/or side effect treatment . - Change number fall - Change neuropsychiatric evaluation , include : - Beck Depression Inventory-II ( BDI-II ) - Mattis Dementia Rating Scale-Second Edition ( DRS-2 ) - Repeatable Battery Assessment Neuropsychological Status ( RBANS ) - Symptom Checklist-90-Revised ( SCL-90-R ) - Wechsler Abbreviated Scale Intelligence ( WASI ) We also compare number day spend hospital follow surgery . Adverse event relate surgery capture .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Idiopathic Parkinson 's disease patient identify OHSU movement disorder neurologist deep brain stimulation surgical candidate Subjects already undergone implantation DBS electrodes 2.Age &lt; 18 year Surgical target site subthalamic nucleus globus pallidus par interna Subjects choose undergo MER framebased stereotaxis placement electrode . Patients receive follow neurology care DBS programming center OHSU .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Deep Brain Stimulation</keyword>
</DOC>